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Abstract
Background: Mulibrey nanism (MUL) is a rare growth restriction disorder with
multiple organ manifestations caused by genetic defects affecting the TRIM37
protein. A perimyocardial heart disease is the most serious manifestation. Many MUL
children appear to suffer from airway obstruction related to infection or exercise,
prompting use of inhaled therapies. Asthma medication is continued up to
adolescence or even to adulthood due to persisting of symptoms. The pulmonary
pathophysiology has previously not been evaluated in any MUL cohort.
Methods: Thirty three finnish MUL patients (median age 20 years) were investigated
with several lung function tests: spirometry with bronchodilatation test, single‐breath
diffusing capacity for carbon monoxide, single‐breath lung volume measurements
with helium dilution, and thoracic gas volume, airway resistance and specific
conductance measurements with a body plethysmograph. As MUL typically affects
body proportions, all variables were compared with reference values and with
predicted values calculated from sitting height.
Results: Total lung capacity and forced vital capacity were markedly reduced (total
lung capacity [TLC] and forced vital capacity [FVC], P < .001, 51%‐63% of predicted)
and also forced expiratory volume in the first second was reduced (FEV1; P < .001,
47%‐57%). No signs of airway obstruction was seen (normal FEV1/FVC and specific
airway conductance SGaw). Diffusing capacity (DLCO) was decreased (P < .001,
60%‐67%) but when related to alveolar volume it was increased (DLCO/VA, P < .001,
130%‐148%). Bronchodilatation suggesting active asthma (FEV1 change ≥12% and
≥200mL) was found only in one patient.
Abbreviations: BNP, B‐type natriuretic peptide; DLCO, diffusing capacity for carbon monoxide; DLCOc, hemoglobin corrected diffusion capacity; FEV1, forced expiratory volume in
1 second; FRC, functional residual capacity; FVC, forced vital capacity; LVEF, left ventricular ejection fraction; MEF25, maximal expiratory flow at 25% of FVC; MEF50, maximal expiratory flow
at 50% of FVC; MUL, Mulibrey nanism; PEF, peak expiratory flow; Raw, airway resistance; RV, residual volume; RVEF, right ventricular ejection fraction; sGaw, specific airway conductance;
TGV, thoracic gas volume; TLCb, total lung capacity in body plethysmography; TLCHe, total lung capacity with helium dilution technique; VA, alveolar volume; VC, vital capacity.
Johanna Sivunen and Päivi Piirilä contributed equally to this work.
Conclusion: MUL patients typically have volume restriction of the lungs, but function
of the pulmonary tissue remains intact. Evidence of asthma in lung function testing at
adult age is rare.
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1 | INTRODUCTION
Mulibrey nanism (MUL) is a rare inherited disorder with multiorgan
manifestations caused by mutations in TRIM37 gene encoding
TRIM37 protein with unknown function. Growth restriction with
prenatal onset is the most essential clinical feature. Patients are
short (adult height less than 3 SD below population median) and
gracile, with a small and bell‐shaped thoracic cage, thin ribs, and
slender extremities (Figures 1 and 2). The head growth is normal, and
mild muscular hypotonia is the only neurological abnormality.1
In children with MUL, respiratory tract infections together with
feeding difficulties are the most common problems. In an earlier study
from our group, 47% of the infants were diagnosed with pneumonia
before the age of 2 years. Further, 25% of the infants had episodes of
respiratory failure induced by an infection.1 The reason for this
susceptibility is not known and no immunological defects have been
established. Our institution has since the 1970s administrated the clinical
care and follow‐up of Finnish MUL patients. According to our clinical
experience, a substantial part of MUL patients appear to suffer from
airway obstruction related to infection or exercise, prompting use of
inhaled therapies during childhood. Continuation of asthma medication is
due to persisting of symptoms up to adolescence or even to adulthood.
In thoracic X‐rays the patients usually have normal pulmonary
findings. The most severe manifestation of MUL is cardiopathy with
constriction of the pericardium and restriction of the myocardium,
leading to diastolic dysfunction.2,3 However, respiratory symptoms
are present also in patients with no clinical signs of heart disease. The
aim of this study was to characterize the lung function disturbances
of MUL patients in detail, an issue not systematically studied before.
2 | PATIENTS AND METHODS
We examined the lung function of 33 Finnish MUL patients, median
age 20 years (15–49), who visited Helsinki University Hospital
(Table 1). The median height was 152.5 cm for men and 137.7 cm for
women, and the median estimated height based on sitting height was
161.5 and 144.0 cm, respectively. The sitting height was measured
for better estimation of the height to calculate reference values of
lung function. The estimated height was calculated by dividing the
sitting height by 0.52 for men and by 0.53 for women.4 The median
upper‐to‐lower body segment ratio was 1.21 for men and 1.26 for
women. The mean body‐mass‐index [BMI] was normal and no patient
showed significant obesity (BMI > 30 kg/m2). Five patients (15%)
were current smokers and five were ex‐smokers. Apart from 4 of
16 women, inhaled steroids were not used in the preceding 4 weeks
before lung function tests. The study was approved by the
Institutional ethical review board at the University of Helsinki
F IGURE 1 (A, B) 24‐year‐old male
Mulibrey nanism patient (written consent
obtained from patient) [Color figure can be
viewed at wileyonlinelibrary.com]
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(approval numbers 420/E7/2001 and HUS/1538/2016§38). Informed
consent was obtained from all patients or their guardians.
2.1 | Spirometry
Spirometry was performed using a rolling seal spirometer (CPI 220;
Cardio Pulmonary Instruments; Houston, TX) connected to a
microcomputer system (Medikro 202; Medikro Oy; Kuopio, Finland)
according to European recommendations of the time of the studies.5
The results from the envelope curve of at least three superimposed
forced expiratory flow‐volume curves were recorded. Slow vital
capacity (VC), forced vital capacity (FVC), forced expiratory volume
in 1 second (FEV1), peak expiratory flow (PEF) as well as maximal
expiratory flow rate at 50% and 25% of the FVC (MEF50 and MEF25)
were determined with the patient in the sitting position. Reference
values for Finnish adults and adolescents were used.6,7 Bronchodi-
latation tests with inhaled salbutamol aerosol (0.4 mg) (Ventoline,
Glaxo, UK) were performed to 17 males and 15 females.
2.2 | Diffusing capacity
A single‐breath diffusing capacity test (Master Lab; Erich Jaeger,
Würzburg, Germany) was used for measurement of diffusing capacity
of the lungs for carbon monoxide (DLCO) and total lung capacity with
single‐breath helium dilution method (TLCHe). The reference values
for adult Finns and European adolescents were used, obeying the
guidelines of the European Respiratory Society.8-10 DLCO was
corrected for the patient’s actual hemoglobin concentration (DLCOc).
The mean value of two successive measurements was recorded for
the analysis and compared with the predicted values.
2.3 | Body plethysmography
Thoracic gas volume (TGV), airway resistance (Raw), and specific
airway conductance (sGaw) were measured using a constant‐volume
body plethysmograph (Bodyscreen II; Erich Jaeger; Wurzburg,
Germany) during tidal breathing timed with a metronome
(30/min).11 The mean value of three to five determinations was
recorded for analysis. VC, TLC measured using body plethysmograph
(TLCb), residual volume (RV), and functional residual capacity were
calculated based on slow spirometric measurements and TGV
measurement. Reference values of adult Finns and European
adolescents were used.9,11 The nonventilated lung compartment
was calculated as the difference between TLCb and TLCHe.
2.4 | B‐type natriuretic peptide (BNP)
Plasma BNP was determined from fasting venous blood samples
taken from an antecubital vein after the patient had rested for
15minutes in the sitting position using a standard method. The upper
limit of the normal range was 18.7 ng/L.3
2.5 | Statistics
The statistical analysis was performed using IBM SPSS Statistics 22
(IBM Corporation, Armonk, NY). Measured values of lung function
variables were compared with two sets of reference values; those
based on actual height and those conducted from sitting height.
Comparisons were made with paired T‐test for normally distributed
parameters and otherwise with the Wilcoxon signed‐rank test.
Different patient groups were compared with Student T‐test for
normally distributed parameters and otherwise with the Mann‐Whitney
U‐test. P values below 0.05 were considered statistically significant.
3 | RESULTS
The lung function of 33 Finnish MUL patients was investigated with
various lung function tests (Table 2).
3.1 | Spirometry and body plethysmography
All measured lung volumes (VC, FVC, TLCHe, and TLCb) were
significantly lower (P < .05, mostly <.001) than the reference values
based either on actual or estimated height. Lung volumes were about
50% of predicted, based on estimated height (range 45.1–53.6%).
Most values were significantly higher as percent of predicted values
compared with those measured as percent of estimated reference
values. No significant difference of percentage values was found
between men and women by any lung volume variable (Figure 3A).
Also the parameters FEV1 and MEF50 were significantly reduced
(P < .001, men and women), as well as PEF (P < .01 in women, P < .001
in men, range 33.0‐67.4% of predicted). FEV1/FVC of women (median
0.84) did not differ from predicted values and that of men (median
0.84) was slightly lower than predicted (P < .05 compared with
F IGURE 2 Typical bell‐shaped thorax with thin ribs in a 15‐year‐
old female mulibrey nanism patient
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estimated height predicted values). Raw was higher than estimated
height predicted (P < .001 in women and P < .01 in men), but sGaw did
not differ from the predicted values, except for one patient. RV/TLC
was not elevated in any comparisons. In Figure 3B and 3C individual
values of FEV1/FVC, RV/TLC, SGaw and Raw are shown.
3.2 | Diffusing capacity
DLCO corrected with actual hemoglobin (DLCOc) was significantly
reduced both in women and men (P < .001, around 60‐67% of estimated
height predicted values), but when related to effective alveolar volume
(DLCOc/VA) it was significantly higher than predicted values (P < .001,
range 130‐148% of estimated height predicted values). Individual data
are presented in Figure 3D. Nonventilated lung compartment was on
average normal (0.21‐0.23l).
3.3 | Bronchodilatation test
In the bronchodilatation test (Table 3) the mean increase of FVC was
3% in men and 1% in women and in every subject less than 47ml. The
mean increase of FEV1 was 98ml in men and 71ml in women (both
5%). Four of 15 women and 1 of 17 men showed an increase of FEV1
at least by 12%. Among those, the absolute FEV1 change varied from
160 to 230ml. Only one patient showed an increase of FEV1 at least
by 12% and 200ml, suggesting asthma.12
The female patients on steroid medication showed significantly
lower values of FEV1/FVC and MEF50 in absolute values and as %
predicted, as well as FEV1/FVC as % estimated height predicted, than
those with no medication. Likewise, Raw values were higher in
patients on medication.
3.4 | Cardiac parameters
Pericardiectomy had earlier been performed to nine male (53%) and four
female (25%) patients. The heart function and structure of all patients
was studied earlier with pulsed Doppler echocardiography.3 Significant
diastolic dysfunction of the left ventricle13 was diagnosed in seven males
(41%) and four females (25%). The BNP level in blood was slightly
elevated (over 18.7 ng/L) in 6 of 17 males (35%) and 11 of 16 females
(69%). The lung function variables showed no significant differences,
when patients with diastolic dysfunction were compared with patients
with normal heart function. Right ventricular ejection fraction (RVEF) did
not correlate significantly with the lung function variables. For further
information on cardiac parameters please see Table 1.
4 | DISCUSSION
The results show marked volume restriction of the lungs in MUL
patients; VC and TLC were around 50% of the predicted values. The
ventilatory capacity in terms of FEV1 was also markedly limited
TABLE 1 Anthropometric characteristics and some cardiac data of the 33 mulibrey nanism patients
Male Female Total
N (%) 17 (52) 16 (49) 33 (100)
Age, years 25.05 (15.93‐38.77) 29.03 (15.21‐49.96) 20.75 (15.21‐49.96)
Weight, kg 46.0 (23.0‐57.9) 39.9 (30.0‐54.1) 40.0 (23.0‐57.9)
Measured height, cm 152.5 (137.0‐162.4) 137.7 (130.0‐152.0) 145.8 (130.0‐162.4)
Sitting height, cm 84.0 (74.0‐88.0, n = 15) 76.3 (71.0‐85.5, n = 15) 80.0 (71.0‐88.0, n = 30)
Estimated heighta, cm 161.5 (142.3‐169.2, n = 15) 144.0 (134.0‐161.3, n = 15) 152.8 (134.0‐169.2, n = 30)
Upper‐to‐lower body segment ratiob 1.21 (1.11‐1.40, n = 15) 1.26 (1.13‐1.36, n = 15) 1.23 (1.11‐1.40, n = 30)
BMI, kg/m2 19.8 (12.3‐23.6) 21.1 (16.8‐28.2) 20.3 (12.3‐28.2)
Steroid medicationc, n (%) 0 (0) 4 (25) 4 (12)
Current smoker, n (%) 3 (18) 2 (13) 5 (15)
Diastolic dysfunctiond, n (%) 7 (41) 4 (25) 11 (33)
Pericardiectomy performed earlier, n (%) 9 (53) 4 (25) 13 (39)
RVEF, % 46.5 (31‐68, n = 16) 53 (39‐66, n = 14) 48.5 (31‐68, n = 30)
LVEF, % 55 (37‐71, n = 16) 68.5 (57‐77, n = 14) 62.5 (37‐77, n = 30)
BNP, ng/Le 9.3 (4.0‐90.0) 23.0 (9.1‐71.0) 19.0 (4.0‐90.0)
Note: Values are in median (range) unless else specified.
Abbreviations: BMI, body mass index; BNP, B‐type natriuretic peptide, RVEF, right ventricular ejection fraction, LVEF, left ventricular ejection fraction, E,
flow velocity in early diastole, A, flow velocity at atrial contraction.
aEstimated total height derived from sitting height.
bSitting height/(height − sitting height).
cCorticosteroid use during 4 wk before the lung function tests.
dE/A relation of mitral flow velocity >2.0 together with the longer duration of A wave in the pulmonary vein than in the mitral inflow in pulsed Doppler
echocardiography.2
eNormal value < 18.7 ng/L.
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TABLE 2 Results of spirometry, body plethysmography and diffusing capacity measurements
Measured value, Predicted value,
Percent of predicted
value, %
Estimated height
predicted valuea,
Percent of estimated
height predicted
valuea, %
n (f) = 16 n(f) = 16 n (f) = 16 n(f) = 13 n (f) = 13
n (m) = 17 n(m) = 17 n(m) = 17 n(m) = 13 n (m) = 13
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
VC, l
f 1.66 (0.4) 2.70 (0.3)*** 61.4 (9.9) 3.09 (0.4)*** 54.8 (8.1)
m 2.27 (0.7) 3.96 (0.6)*** 56.7 (11.3) 4.55 (0.4)*** 50.0 (11.2)
FVC, l
f 1.64 (0.4) 2.71 (0.3)*** 61.0 (11.9) 3.09 (0.4)*** 53.6 (9.4)
m 2.26 (0.7) 3.95 (0.6)*** 56.7 (11.7) 4.51 (0.4)*** 50.3 (11.6)
FEV1, l
f 1.38 (0.4) 2.40 (0.3)*** 57.1 (9.0) 2.71 (0.4)*** 52.4 (8.7)
m 1.88 (0.6) 3.58 (0.6)*** 52.1 (11.8) 4.02 (0.3)*** 46.5 (11.8)
FEV1/FVC, %
f 83.8 (8.3) 88.4 (2.8) 95.1(11.1) 87.6 (2.9) 97.6 (10.0)
m 84.3 (9.1) 90.8 (3.5)** 92.9 (9.1) 89.1 (3.6)* 93.5 (8.3)
PEF, l/s
f 4.42 (1.2) 6.17 (1.0)** 71.3 (12.4) 6.85 (0.5)** 67.4 (13.4)
m 5.55 (1.7) 8.91 (1.7)*** 63.1 (16.5) 9.89 (0.4)*** 55.8 (14.7)
MEF50, l/s
f 1.71 (0.7) 3.79 (0.6)*** 44.4 (14.0) 4.21 (0.5)*** 43.1 (14.9)
m 2.15 (0.9) 5.88 (1.2)*** 37.7(16.0) 6.27 (0.6)*** 33.0 (12.7)
Raw, kPa*s/L
f 0.39 (0.1) 0.24 (0.1)** 171.4 (62.6) 0.18 (0.0)*** 208.9 (66.1)
m 0.33 (0.2) 0.16 (0.1)** 258.4 (182.5) 0.11 (0.0)** 320.6 (201.0)
SGaw, l/kPa*s
f 2.24 (0.7) 1.97 (0.1) 113.6 (35.0) 1.95 (0.1) 118.3 (39.4)
m 2.16 (0.9) 2.34 (0.3) 93.9 (43.2) 2.26 (0.1) 92.0 (33.7)
TLCb, l
f 2.39 (0.4) 3.83 (0.6)*** 62.9 (10.5) 4.54 (0.6)*** 52.6 (5.9)
m 3.29 (0.7) 5.53 (1.0)*** 59.9 (9.3) 6.55 (0.5)*** 51.1 (7.4)
RV, % TLC
f 29.9 (6.4) 30.3 (3.7) 99.9 (24.4) 32.8 (2.3)* 89.3 (15.9)
m 28.7 (7.8) 27.0 (2.9) 108.2 (34.1) 29.3 (1.9) 101.9 (25.5)
TLCHe, l
f 2.18 (0.5) 4.06 (0.4)*** 54.7 (10.0) 4.56 (0.5)* 47.9 (7.2)
m 3.07 (0.8) 5.82 (0.5)*** 53.5 (10.2) 6.56 (0.5)*** 47.2 (8.5)
DLCOc, mmol/min/kPa
f 4.16 (1.0) 6.27 (0.4)*** 66.1 (14.0) 7.02 (0.5)*** 60.5 (12.8)
m 6.04 (1.4) 8.89 (0.8)*** 67.2 (12.2) 9.48 (0.6)*** 63.5 (11.2)
DLCOc/VA, mmol/min/kPa/l
f 2.21 (0.3) 1.70 (0.1)*** 130.4 (16.4) 1.69 (0.1)*** 133.5 (17.7)
m 2.27 (0.3) 1.71 (0.1)*** 132.7 (17.4) 1.58 (0.1)** 141.5 (20.5)
TLCb – TLCHe, l
f 0.21 (0.1)
m 0.23 (0.2)
Note: The reference values used are for adults Viljanen 1982, for adolescents < 18 y Koillinen 1998 (spirometry) and Polgar 1979 (diffusing capacity,
plethysmography)
Abbreviations: DLCOc, hemoglobin corrected diffusing capacity; DLCOc/VA, specific diffusing capacity (total diffusion capacity related to alveolar
volume); f, female; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; m, male; MEF50, maximal expiratory flow at 50% of FVC;
MEF25, maximal expiratory flow at 25% of FVC; PEF, peak expiratory flow; Raw, airway resistance; SGaw, specific airway conductance; RV, residual
volume; TLCb, total lung capacity in body plethysmography; TLCHe, total lung capacity with helium dilution technique; TLCb‐TLCHe, nonventilated lung
compartment; VC, vital capacity.
aPredicted value based on estimated height derived from sitting height.
*P < .05.
**P < .01.
***P < .001.
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(around 50% of predicted), but the variables characteristic for airway
obstruction, FEV1/FVC and SGaw, were normal. In addition, the ratio
of RV and total lung capacity was not elevated suggesting no
significant hyperinflation in the lungs.14 Furthermore, the difference
between compressible TGV and the volume measured with gas
dilution (TLCb‐TLCHe) was not increased, excluding abnormal air
trapping in small airways.14,15 Our conclusion is that patients with
MUL do not typically have airway obstruction, but they do have lung
volume restriction, which decreases the ventilatory capacity in terms
of decreased FEV1.
In clinical practice, MUL patients have often been treated
symptomatically with asthma medicines. However, according to this
study, active asthma is not typical in MUL patients. In this material
only one subject showed significant improvement of FEV1 in the
bronchodilatation test suggesting asthma. Since other signs of airway
obstruction were mostly absent, but restrictive failure was typical, it
is probable, that the decreased PEF and respiratory symptoms can be
caused by other reasons than obstruction. Such reasons may be
reduced lung volume, but also decreased muscular strength, low
compliance, anthropometric features, and pulmonary hypertension.
The diffusing capacity of the lungs (DLCOc) was reduced to
approximately 60% of predicted but the reduction was slightly
smaller than that of lung volumes. Thus, the specific diffusing
capacity (DLCOc/VA) was even higher than the predicted values. This
finding rules out any lung tissue dysfunction. On the contrary, it may
suggest that the lung tissue is more dense, implying that a normal
number of healthy alveoli are located in an abnormally small thoracic
cage. According to an earlier study, an experimentally induced outer
restriction does not increase the RV/TLC,16 a result similar to our
findings.
The extremities of MUL patients are typically short in proportion
to the height. Also in our patients, the median upper‐to‐lower body
segment ratio was 1.21 for men and 1.26 for women. This is higher
than in the general population; in a European cohort of young adults,
these measures were approximately 1.06 for men and 1.11 for
women.17 Reference values based on sitting height have been used
for patients with varying anthropometric relations.18,19 Also in our
cohort, to get a more realistic assessment of the lung function, we
calculated reference values based on estimated height derived from
sitting height. When these reference values were used, the lung
function parameters showed significantly lower results. MUL patients
have also a narrow thorax and relative macrocephaly.1 Consequently,
no available reference values for lung function are fully suitable in
this patient group. Also, the common criterion of asthma (FEV1
change 12% and 200mL) may be too strict, as the lung volumes are
smaller than normal.
The heart disease is the most serious component of MUL, and
patients are often pericardiectomized.3,20 A typical consequence of
F IGURE 3 Individual lung values: A, low lung volume values VC, FVC, TLCHe and TLCb; B, normal FEV1/FVC and RV/TLC; C, normal sGaw
and high Raw; D, reduced DLCOc, but normal or high DLCOc/VA. DLCOc, hemoglobin corrected diffusion capacity; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity; Raw, airway resistance; RV, residual volume; sGaw, specific airway conductance; TLC, total
lung capacity; TLCb, total lung capacity in body plethysmography; TLCHe, total lung capacity with helium dilution technique; VA, alveolar
volume; VC, vital capacity
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the heart disease is diastolic dysfunction. In this condition, the RVEF is
supposed to give more accurate rating of the heart function than the left
ventricular ejection fraction (LVEF).21 In our study, the RVEF was
decreased, but did not correlate with lung function parameters. This
suggests that in our patients, the lung function independently affects the
cardiorespiratory performance. Volume restriction of the thoracic cage
may also contribute to cardiac morbidity by altered intrathoracic
pressures. Furthermore, some MUL patients experience a reversible
phase of chronic hypoxemia demanding continuous oxygen therapy from
several months to some years in early childhood, unexplained by
concurrent heart disease (Valmari P, unpublished observation). These
younger MUL children may have a more severe lung pathophysiology
than the adolescents and young adults, who have survived and possibly
adapted to their restrictive failure. The respiratory failure in young MUL
children is a subject for further studies.
BNP is a biomarker, which increases in heart failure, and low
levels of BNP have been reported to rule out heart failure.22 In
earlier literature, BNP has been reported to increase in pulmonary
arterial hypertension.23-25 It remains unknown, however, whether
subclinical increases of pulmonary arterial pressure have any
influence on the BNP levels in less severe MUL.
As 33% of our patients had diastolic dysfunction and 13% had
decreased LVEF, it is possible that some subjects had increased blood
volume in pulmonary capillaries. Thereby induced pulmonary
congestion may temporarily increase single‐breath diffusing capacity
for carbon monoxide and slightly reduce lung volumes.26 Thus, the
heart failure might interfere with pulmonary restriction. Further
studies with parallel analysis of the cardiopulmonary performance
and pulmonary function are needed to give more information about
the source of exercise‐induced symptoms in these patients.
Despite the possible effect of the heart disease on the lungs, it is
likely, that the main reason for the restrictive failure in the lung
function of MUL patients is the abnormally small bony thorax.
Similarly, other types of deformation of bony thorax, such as
cyphoscoliosis, may cause respiratory impairment. Nocturnal non-
invasive ventilation has been used in conditions causing volume
restriction of the lungs.27-29 The application of similar therapies could
eventually be studied also in MUL patients.
There is a limited number of studies concerning lung function in
conditions causing growth failure. In achondroplasia, the vital
capacity is reduced but the RV/TLC ratio is normal in a similar way
as in MUL. Children with achondroplasia are also at risk of sleep‐
disordered breathing.30,31 In diastrophic dysplasia, another skeletal
dysplasia causing short‐limbed short stature, the lung volumes tend
to be normal, but PEF values are abnormally low. This indicates an
impaired function of the chest cage and respiratory muscles.32 In
growth hormone deficiency, an impairment of lung function is caused
not solely by indirect (height‐mediated) effect, but also by a direct
effect of growth hormone to the lungs.33 In MUL, the restrictive
failure may be partly explained by all of these factors.
In this study, the main limitation was the lack of healthy
controls. Normal lung function varies strongly with age, sex, and
height. Since MUL patients have a grave growth failure, no similar
group of healthy adults exists and we were forced to depend on
reference values instead. The results concerning asthma diagnosis
must be related to the fact that 12% of the patients (4 of 33) were
using inhalation steroids at time of the study. Additional testing,
such as metacholine challenge, could possibly reveal more asthma
than our study protocol did.
In our study, we estimated the functional condition of the lung
parenchyma by its diffusing capacity. A biopsy would have given
more information, but was not possible due to ethical reasons. In our
earlier work, pleurae seemed thicker and more dense than normal in
autopsy samples. Pleural adhesions and pleural leaves adherent to
each other were also observed, as were slight to gross adhesions in
the sternal area between the heart and thoracic wall in patients past
pericardiectomy.34 Thereby it is possible, that there is constriction
not only in pericardium, but also in pleura. These changes might also
influence the respiratory system.
In conclusion, the present findings indicate that patients with
MUL typically have volume restriction of the lungs, but function of
the pulmonary tissue remains normal. Airflow limitation of the lungs
does not seem to be a typical feature in these patients, and evidence
of asthmatic bronchoconstriction in lung function testing at adult age
is rare. The results suggest that in MUL, lungs with no apparent
parenchymal dysfunction are constricted by an abnormally small
thoracic cage. However, also heart dysfunction and pleural adhesions
may interfere with pulmonary restriction.
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TABLE 3 Change in spirometric variables after bronchodilatation
Gender n
Change %, mean (SD),
range
Change mL, mean (SD),
range
FVC
f 15 0.7 (2.9), −5 to +5 14.7 (40.2), −60 to +90
m 17 2.8 (5.0), −6 to +11 46.5 (101.8), −140 to +190
FEV1
f 15 5.4 (6.6), −2 to +18 70.7 (83.1), −20 to +230
m 17 5.4 (4.8), −5 to +13 97.7 (100.7), −110 to +310
PEF
f 15 10.9 (14.7), −18 to +40
m 17 15.8 (12.4), −6 to +42
Abbreviations: F, female; FEV1, forced expiratory volume one second; FVC,
forced vital capacity; M, male; PEF peak expiratory flow; VC vital capacity.
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